Abstract

Thyroid carcinoma is the most frequent endocrine neoplasia. Different types of thyroid carcinoma are described: well-differentiated papillary thyroid carcinoma (PTC), poorly differentiated thyroid carcinoma (PDTC), follicular thyroid carcinoma (FTC), anaplastic thyroid carcinoma (ATC), and medullary thyroid carcinoma (MTC). MTC is inherited as an autosomal dominant trait in 25% of cases. The genetic landscape of thyroid carcinoma has been largely deciphered. In PTC, genetic alterations have been found in about 95% of tumors: BRAF mutations and RET rearrangements are the main genetic alterations. BRAF and RAS mutations have been confirmed to play an important role also in PDTC and ATC, together with TP53 mutations that are fundamental in tumor progression. It has also been clearly demonstrated that telomerase reverse transcriptase (TERT) promoter mutations and TP53 mutations are present with a high-frequency in more advanced tumors, frequently associated with other mutations, and their presence, especially if simultaneous, is a signature of aggressiveness. In MTC, next-generation sequencing confirmed that mutations in the RET gene are the most common molecular events followed by H-RAS and K-RAS mutations. The comprehensive knowledge of the genetic events responsible for thyroid tumorigenesis is important to better predict the biological behavior and better plan the therapeutic strategy for specific treatment of the malignancy based on its molecular profile.

Highlights

  • Thyroid carcinoma is the most frequently reported endocrine neoplasia and represents3–4% of all human tumors

  • To their histological features, different types of thyroid carcinoma are described: well-differentiated papillary thyroid carcinoma (PTC, 75–80%), poorly differentiated thyroid carcinoma (PDTC, 5–7%), follicular thyroid carcinoma (FTC, 8–10%), anaplastic thyroid carcinoma (ATC, 2–3%), which originate from follicular cells, and medullary thyroid carcinoma (MTC, 5–7%), which derives from parafollicular C-cells (Figure 1) [1]

  • In PTC, the results of the study of the TGCA study definitively demonstrated that genetic alterations are present in about 95% of tumors and that two main classes of tumors (BRAF- and RAS-like), each with their own clinical and biological behavior, can be distinguished

Read more

Summary

Introduction

Thyroid carcinoma is the most frequently reported endocrine neoplasia and represents. RET/PTC rearrangements are characterized highbut prevalence in post-Chernobyl thyroid tumors (87%) highlighted a strong by t occurrence of different breakpoints giving originexposure to longer or shorter chimeras relation between. T been proposed by in vitro experiments that the spatial proximity of the loci involved high prevalence of RET/PTC in post-Chernobyl thyroid tumors (87%) highlighted a stro in RET/PTC rearrangements predisposesand theirradiation mis-joining as a consequence doublerelation between. Years later, it h stranded breaks produced by ionizing radiation [12,13,14,15]. A low prevalence of RET rearrangements, mainly in carcinoma associated with a differentiated component, have been found in PDTC and ATC [25]

Other Rearrangements
BRAF Point Mutations
TERT Mutations
Schematic
RAS Mutations
EIF1AX Mutations
TP53 Mutations
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call